CD274 and cancer: This phenomenon has been reported as “adaptive immune resistance” [38,39,49,50] and is a major mechanism of immune escape in several tumors, as evidenced by the successful results of anti-PD-1/PD-L1 antibodies in cancer immunotherapy [38,49].